Group 1 - The company TianTan Bio (SH 600161) held its 26th meeting of the 9th Board of Directors on October 23, 2025, in Beijing, where it reviewed the proposal to adjust the blood source management structure [1] - For the first half of 2025, the company's revenue composition was 99.68% from the biopharmaceutical sector and 0.32% from other businesses [1] - As of the report date, TianTan Bio's market capitalization was 37.7 billion yuan [1] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, indicating a hot secondary market for biopharmaceuticals [1] - Despite the thriving secondary market, the primary market for fundraising in the biopharmaceutical sector is experiencing a cooling trend [1]

证券代码：600161 证券简称：天坛生物 公告编号：2025-051 北京天坛生物制品股份有限公司 第九届董事会第二十六次会议决议公告 详见同日披露的《北京天坛生物制品股份有限公司 2025 年第三季度报告》。 二、审议通过《关于调整血源管理架构的议案》 同意公司撤销血源管理中心，并设立血源管理部和血源管理大区。 表决结果：9 票同意，0 票反对，0 票弃权。 三、审议通过《关于天坛武汉收购武生松滋单采血浆站有限公司 1%股权项目的 议案》 本议案已经董事会战略与投资委员会事前认可。 同意公司下属国药集团武汉生物制药有限公司（以下简称"天坛武汉"）以评估 价格 22.266 万元收购武生松滋单采血浆站有限公司（以下简称"松滋浆站"）自然人 股东所持松滋浆站 1%股权。收购完成后，天坛武汉持有松滋浆站 100%股权。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）第九届董事会第二十六次 会议于 2025 年 10 月 13 日发出会议通知，于 2025 年 10 月 23 日以 ...

Financial Performance - The company's operating revenue for Q3 2025 was CNY 1,354,678,903.64, representing a year-on-year increase of 9.96%[4] - The total profit for the period decreased by 42.14% to CNY 309,027,126.09 compared to the same period last year[4] - The net profit attributable to shareholders of the listed company was CNY 186,124,194.35, down 42.84% year-on-year[4] - The basic earnings per share for the period was CNY 0.09, reflecting a decrease of 42.84% compared to the previous year[4] - Total operating revenue for the first three quarters of 2025 reached ¥4,465,071,868.98, an increase of 9.6% compared to ¥4,073,361,821.56 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was ¥1,120,457,127.99, a decrease of 21.5% from ¥1,427,390,948.39 in the previous year[20] - The total comprehensive income for the first three quarters was ¥1,120,457,127.99, compared to ¥1,446,486,664.53 in the same period last year, reflecting a decline of 22.5%[20] - The company's net profit for the first three quarters of 2025 reached CNY 544,134,446.17, a significant increase from CNY 259,957,121.71 in the same period of 2024, representing a growth of approximately 109.5%[30] - Operating profit for the first three quarters of 2025 was CNY 549,116,963.48, compared to CNY 260,010,766.34 in 2024, indicating an increase of about 111.1%[30] - The total profit for the first three quarters of 2025 amounted to CNY 544,099,009.28, up from CNY 260,002,186.05 in 2024, reflecting a growth of approximately 109.5%[30] Assets and Liabilities - The total assets at the end of the reporting period were CNY 16,550,873,344.89, an increase of 4.29% from the end of the previous year[5] - The total assets of the company as of September 30, 2025, amounted to RMB 16,550,873,344.89, an increase from RMB 15,869,522,217.56 as of December 31, 2024, reflecting a growth of approximately 4.3%[14] - Current assets reached RMB 8,271,318,830.98, up from RMB 7,722,300,180.61, indicating an increase of about 7.1%[14] - The company's total liabilities increased to ¥1,603,830,000.89, compared to ¥1,336,323,636.94 in the previous year, reflecting a growth of 20%[19] - The total liabilities as of September 30, 2025, were CNY 55,324,986.55, compared to CNY 11,237,997.93 at the end of 2024[27] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 116,895,028.07, showing a significant decrease of 91.00%[4] - Operating cash flow for the first three quarters of 2025 was CNY 116,895,028.07, a significant decrease of 91% compared to CNY 1,298,751,779.50 in the same period of 2024[23] - The company's cash inflow from operating activities decreased significantly, indicating potential challenges in cash generation[23] - The net cash flow from operating activities for the first three quarters of 2025 was negative at CNY -37,224,302.46, compared to CNY -5,462,517.08 in 2024, indicating a decline in cash flow from operations[33] - Cash inflow from investment activities in the first three quarters of 2025 totaled CNY 1,332,481,773.66, while cash outflow was CNY 400,412,582.21, resulting in a net cash flow of CNY 932,069,191.45 from investment activities[33] Investments and Expenditures - The company's fixed assets grew to RMB 3,671,606,168.52 from RMB 3,307,444,385.66, indicating an increase of about 11%[14] - The company reported a significant increase in development expenditures, rising to RMB 496,637,895.28 from RMB 390,748,316.33, which is an increase of approximately 27%[14] - The company has increased its investment in fixed assets, with cash payments for fixed assets amounting to CNY 450,530,338.98 in 2025 compared to CNY 734,275,672.10 in 2024[24] Government Support and Market Conditions - The company received government subsidies amounting to CNY 6,410,711.80, which have a lasting impact on profits[11] - The decline in profits was attributed to a decrease in sales prices and an increase in credit impairment losses[8] - Future outlook includes potential market expansion and new product development initiatives to drive revenue growth[21] Shareholder Information - The company has no pledged, marked, or frozen shares among its major shareholders, ensuring stability in ownership[12]

Core Viewpoint - TianTan Biological announced several key decisions made during the 26th meeting of the 9th Board of Directors, including the approval of the Q3 2025 report and structural changes within the company [1] Group 1: Financial Reporting - The Board approved the "Q3 2025 Report," indicating ongoing financial oversight and performance evaluation [1] Group 2: Organizational Changes - The decision was made to dissolve the Blood Source Management Center and establish a Blood Source Management Department and a Blood Source Management Region, reflecting a strategic restructuring [1] Group 3: Acquisitions - TianTan Wuhan agreed to acquire a 1% stake in Songzi Plasma Station for 22,266 yuan, which will result in the company holding 100% ownership of the station [1] Group 4: Management Authority - The Board authorized the General Manager's office to make decisions regarding pre-approval of economic activities, indicating a delegation of decision-making authority [1]

Core Insights - The company reported a third-quarter revenue of 1.355 billion yuan, representing a year-on-year increase of 9.96% [1] - The net profit for the third quarter was 186 million yuan, showing a significant decline of 42.84% [1] - For the first three quarters, the total revenue reached 4.465 billion yuan, with a year-on-year growth of 9.62% [1] - The net profit for the first three quarters was 819 million yuan, which is a decrease of 22.16% compared to the previous year [1]

Core Viewpoint - Tian Tan Biological announced the initiation of Phase III clinical trials for its "Prothrombin Complex Concentrate," developed by its subsidiary Wuhan Biological Pharmaceutical, following the completion of ethical review and preparatory work for clinical enrollment [1] Group 1: Product Development - The Prothrombin Complex Concentrate is primarily used for the treatment of congenital and acquired deficiencies of coagulation factors II, VII, IX, and X, which include conditions such as Hemophilia B, anticoagulant overdose, and vitamin K deficiency [1]

（一） 产品信息 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司下属国药集团武汉生物制药有限公司（以下 简称"天坛武汉"）研制的"人凝血酶原复合物"已完成临床伦理审查、临床入 组前准备等工作，于近日正式开展Ⅲ期临床试验，现将有关信息披露如下： 一、 概况 证券代码：600161 证券简称：天坛生物 公告编号：2025-050 北京天坛生物制品股份有限公司 关于下属企业药品临床试验进展的公告 | 产品 | | 获得临床试验批准 | | 注册 | 剂 | 研发投入 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | 适应症 | 通知书时间和编号 | 规格 | 分类 | 型 | （万元） | | | 本品主要用于治疗先天性和获得 | | | | | | | | 性凝血因子Ⅱ、Ⅶ、Ⅸ和Ⅹ缺乏 | | | | | | | | 症（单独或联合缺陷）包括： | | | | | | | | 1.凝血因子Ⅱ、Ⅶ、Ⅸ和Ⅹ缺乏 | | | | | | | | 症，包 ...

Core Viewpoint - Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. has received the Drug GMP Compliance Inspection Notice and the updated Drug Production License, indicating the completion of the production site change for the product "Recombinant Human Coagulation Factor VIII" and the potential for expanded production capacity [1][4]. Group 1: GMP Compliance Inspection - Chengdu Rongsheng received the Drug GMP Compliance Inspection Notice from the Sichuan Provincial Drug Administration [1]. - The inspection was conducted from August 18 to August 21, 2025, and concluded that the company complies with the Drug Production Quality Management Standards (2010 revision) and related appendices [2]. Group 2: Drug Production License Changes - The production scope for Chengdu Rongsheng has been updated to include the production of "Recombinant Human Coagulation Factor VIII," limited to registered application use, following the successful GMP compliance inspection [3]. - The production address remains the same: No. 280, Jingyuan Road, Shuangliu District, Chengdu, Sichuan Province [3]. Group 3: Impact on the Company - The product "Recombinant Human Coagulation Factor VIII" was approved for market launch in September 2023, and the production site change was approved in July 2025 [4]. - The completion of the production site change allows for an increase in production scale for the product [4].

证券代码：600161 证券简称：天坛生物 编号：2025-049 北京天坛生物制品股份有限公司 关于下属企业获得《药品GMP符合性检查告知书》及变更 《药品生产许可证》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京天坛生物制品股份有限公司下属成都蓉生药业有限责任公司（以 下简称"成都蓉生"）收到四川省药品监督管理局颁发的《药品 GMP 符合性检查 告知书》和变更后的《药品生产许可证》。成都蓉生已完成"注射用重组人凝血 因子Ⅷ"产品生产场地变更工作，可实现该产品生产规模扩大。现就相关情况公 告如下： 一、 《药品 GMP 符合性检查告知书》相关信息 检查时间：2025 年 8 月 18 日-2025 年 8 月 21 日 检查结论：符合《药品生产质量管理规范（2010 年修订）》及相关附录规 定。 发证机关：四川省药品监督管理局 二、 《药品生产许可证》变更内容 同意成都蓉生生产地址四川省成都市双流区菁园路 280 号的生产范围治疗 用生物制品（注射用重组人凝血因子Ⅷ）（仅限注册申报使用）变更为治疗用生 物 ...

Core Viewpoint - TianTan Biological announced that its subsidiary Chengdu Rongsheng Pharmaceutical has received the GMP compliance inspection notice and the updated drug production license from the Sichuan Provincial Drug Administration, allowing for an expansion in the production scale of "Recombinant Human Coagulation Factor VIII" [1] Group 1 - Chengdu Rongsheng has completed the site change for the production of "Recombinant Human Coagulation Factor VIII" [1] - The GMP compliance inspection was conducted from August 18 to August 21, 2025, and concluded that the company meets the relevant regulations [1] - The updated drug production license allows for the production of therapeutic biological products (Recombinant Human Coagulation Factor VIII) at the new address in Chengdu, Sichuan Province [1]